Pfizer's Tax Rate 'Fiction' Exposed: Pays Less Than Everyone You Know
Numbers used to justify potential corporate inversion 'are largely an accounting fiction,' says Americans for Tax Fairness
Undermining the company's rationale for a Big Pharma mega-merger that would allow it to dodge paying what it owes in taxes, a new report shows that, in fact, Pfizer has "dramatically overstated its corporate tax rates" and is already enjoying a significant competitive advantage over those who pay their fair share.
The world's largest pharmaceutical company, which manufactures Viagra among other drugs, has cited high U.S. corporate tax rates as an argument in favor of a merger with Irish corporation Allergan. The business deal would likely take the form of what's known as a "corporate inversion," allowing Pfizer to renounce its U.S. tax citizenship while retaining its current U.S. headquarters, management structure, and facilities.
"Despite its self-serving claims, Pfizer is not at a competitive disadvantage operating under the U.S. tax system."
--Frank Clemente, Americans for Tax Fairness
But the report from the coalition Americans for Tax Fairness--entitled Pfizer's Tax Dodging Rx: Stash Profits Offshore (pdf)--indicates that Pfizer's effective tax rate on its worldwide income was just 7.5 percent in 2014, compared with the 25.5 percent rate the company reported in its Securities and Exchange Commission (SEC) filings.
Indeed, according to Americans for Tax Fairness, which analyzed the corporation's SEC filings with the help of tax experts, "a fair reading of those filings is that the company's reported income tax rates are largely an accounting fiction."
As the Wall Street Journal explained on Sunday: "Pfizer's accounting methods raise its reported tax rate, without increasing the actual taxes the company pays. More than two-thirds of the company's 2014 tax expense--$2.2 billion out of $3.1 billion--was money the company will actually pay only if and when it chooses to repatriate foreign profits."
Pfizer had as much as $148 billion in profits parked offshore at the end of 2014, on which it has paid no U.S. income taxes. But given that Pfizer alone controls whether, when, and how much of its foreign earnings might actually be repatriated and therefore taxed, the chances of that tax bill being paid are slim.
"Despite its self-serving claims, Pfizer is not at a competitive disadvantage operating under the U.S. tax system," said Americans for Tax Fairness executive director Frank Clemente on Tuesday. "If anything, Pfizer is highly advantaged. An inversion would lock in these current advantages and extend them further, giving Pfizer an even bigger unwarranted tax edge against other American companies that are paying their fair share."
According to the U.S. Congress' Joint Committee on Taxation, the average American pays an income tax rate of 10.1 percent.
We are at a crossroads
This country and this world are at a monumental crossroads. In a few short weeks, US voters will have an opportunity to beat back the forces of fascism and confront the billionaires who are rigging the economy, our media system, and our democracy, making it increasingly impossible for ordinary people to get by. We’re not just talking about the election. We’re talking about what must be done once these fascist elements are vanquished from power. We need a bolder set of solutions than what either major party has so far been willing to offer and a working-class movement ready to fight like hell for it. Trump didn't emerge from nowhere. The conditions that fueled MAGA authoritarianism were created by decades of radical neoliberal economic policies and a corrupt political system dominated by corporate interests. They slashed taxes on the super-rich, promising that the benefits would trickle down. They said giveaways to the corporate titans would make life more affordable for the rest of us. It was all bullshit. And when a bitter, betrayed populace searches for someone to blame, right-wing demagogues have little trouble finding scapegoats. People know when they're being lied to, but you won't hear any of this from the corporate media. Only independent journalism—powered and funded by people who believe in building a better world—can deliver truly trustworthy daily news. Our Fall Campaign is underway, and we need your help. To power our newsroom through the rest of the year, we need to raise $125,000 by midnight on October 31. So if you share our vision, please contribute whatever you can to sustain our work. |
Undermining the company's rationale for a Big Pharma mega-merger that would allow it to dodge paying what it owes in taxes, a new report shows that, in fact, Pfizer has "dramatically overstated its corporate tax rates" and is already enjoying a significant competitive advantage over those who pay their fair share.
The world's largest pharmaceutical company, which manufactures Viagra among other drugs, has cited high U.S. corporate tax rates as an argument in favor of a merger with Irish corporation Allergan. The business deal would likely take the form of what's known as a "corporate inversion," allowing Pfizer to renounce its U.S. tax citizenship while retaining its current U.S. headquarters, management structure, and facilities.
"Despite its self-serving claims, Pfizer is not at a competitive disadvantage operating under the U.S. tax system."
--Frank Clemente, Americans for Tax Fairness
But the report from the coalition Americans for Tax Fairness--entitled Pfizer's Tax Dodging Rx: Stash Profits Offshore (pdf)--indicates that Pfizer's effective tax rate on its worldwide income was just 7.5 percent in 2014, compared with the 25.5 percent rate the company reported in its Securities and Exchange Commission (SEC) filings.
Indeed, according to Americans for Tax Fairness, which analyzed the corporation's SEC filings with the help of tax experts, "a fair reading of those filings is that the company's reported income tax rates are largely an accounting fiction."
As the Wall Street Journal explained on Sunday: "Pfizer's accounting methods raise its reported tax rate, without increasing the actual taxes the company pays. More than two-thirds of the company's 2014 tax expense--$2.2 billion out of $3.1 billion--was money the company will actually pay only if and when it chooses to repatriate foreign profits."
Pfizer had as much as $148 billion in profits parked offshore at the end of 2014, on which it has paid no U.S. income taxes. But given that Pfizer alone controls whether, when, and how much of its foreign earnings might actually be repatriated and therefore taxed, the chances of that tax bill being paid are slim.
"Despite its self-serving claims, Pfizer is not at a competitive disadvantage operating under the U.S. tax system," said Americans for Tax Fairness executive director Frank Clemente on Tuesday. "If anything, Pfizer is highly advantaged. An inversion would lock in these current advantages and extend them further, giving Pfizer an even bigger unwarranted tax edge against other American companies that are paying their fair share."
According to the U.S. Congress' Joint Committee on Taxation, the average American pays an income tax rate of 10.1 percent.
Undermining the company's rationale for a Big Pharma mega-merger that would allow it to dodge paying what it owes in taxes, a new report shows that, in fact, Pfizer has "dramatically overstated its corporate tax rates" and is already enjoying a significant competitive advantage over those who pay their fair share.
The world's largest pharmaceutical company, which manufactures Viagra among other drugs, has cited high U.S. corporate tax rates as an argument in favor of a merger with Irish corporation Allergan. The business deal would likely take the form of what's known as a "corporate inversion," allowing Pfizer to renounce its U.S. tax citizenship while retaining its current U.S. headquarters, management structure, and facilities.
"Despite its self-serving claims, Pfizer is not at a competitive disadvantage operating under the U.S. tax system."
--Frank Clemente, Americans for Tax Fairness
But the report from the coalition Americans for Tax Fairness--entitled Pfizer's Tax Dodging Rx: Stash Profits Offshore (pdf)--indicates that Pfizer's effective tax rate on its worldwide income was just 7.5 percent in 2014, compared with the 25.5 percent rate the company reported in its Securities and Exchange Commission (SEC) filings.
Indeed, according to Americans for Tax Fairness, which analyzed the corporation's SEC filings with the help of tax experts, "a fair reading of those filings is that the company's reported income tax rates are largely an accounting fiction."
As the Wall Street Journal explained on Sunday: "Pfizer's accounting methods raise its reported tax rate, without increasing the actual taxes the company pays. More than two-thirds of the company's 2014 tax expense--$2.2 billion out of $3.1 billion--was money the company will actually pay only if and when it chooses to repatriate foreign profits."
Pfizer had as much as $148 billion in profits parked offshore at the end of 2014, on which it has paid no U.S. income taxes. But given that Pfizer alone controls whether, when, and how much of its foreign earnings might actually be repatriated and therefore taxed, the chances of that tax bill being paid are slim.
"Despite its self-serving claims, Pfizer is not at a competitive disadvantage operating under the U.S. tax system," said Americans for Tax Fairness executive director Frank Clemente on Tuesday. "If anything, Pfizer is highly advantaged. An inversion would lock in these current advantages and extend them further, giving Pfizer an even bigger unwarranted tax edge against other American companies that are paying their fair share."
According to the U.S. Congress' Joint Committee on Taxation, the average American pays an income tax rate of 10.1 percent.